New head of FDA's neuroscience office takes over at crucial time; inside the demise of a prominent mental health tech startup

Taking stock of the drug industry, from the lab to the medicine chest

February 28, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jacquelyn Martin/AP STAT+ | New head of FDA's neuroscience office takes over at crucial time Teresa Buracchio, a physician and 10-year veteran of the FDA, has been named the acting director of the Office of Neuroscience. By Adam Feuerstein and John Wilkerson Opinion: My son's time is running out due to a rare disease. The FDA needs to add more clinical trial flexibility The FDA's once-flexible Division of Rare Diseases and Medical Genetics is taking a more conservative approach to rare disease. By Judy Stecker STAT+ | How Mindstrong's rush to roll out a 'smoke alarm' for mental illness led to its downfall Former Mindstrong employees described how financial pressures and issues with its technology drove the mental health startup's downfall. By Mohana Ravindranath Cliff Hawkins/Getty Images STAT+ | Ascension, Tufts fall short of financial targets in borrowing agreements Prominent health systems like Ascension and Tufts Medicine are falling short of financial targets set out in borrowing agreements. By Tara Bannow

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser